VistaGen Therapeutics Inc - Asset Resilience Ratio
VistaGen Therapeutics Inc (VTGN) has an Asset Resilience Ratio of 30.09% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VTGN working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2026)
This chart shows how VistaGen Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see VTGN total asset value.
Liquid Assets Composition Over Time
This chart breaks down VistaGen Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read VistaGen Therapeutics Inc (VTGN) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $14.61 Million | 30.09% |
| Total Liquid Assets | $14.61 Million | 30.09% |
Asset Resilience Insights
- Very High Liquidity: VistaGen Therapeutics Inc maintains exceptional liquid asset reserves at 30.09% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
VistaGen Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare VistaGen Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for VistaGen Therapeutics Inc (2017–2026)
The table below shows the annual Asset Resilience Ratio data for VistaGen Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 30.09% | $14.61 Million | $48.56 Million | +14.26pp |
| 2025-03-31 | 15.83% | $13.35 Million | $84.34 Million | -- |
| 2024-03-31 | 0.00% | $0.00 | $123.65 Million | -- |
| 2018-03-31 | 0.00% | $0.00 | $11.28 Million | -- |
| 2017-03-31 | 0.00% | $0.00 | $3.71 Million | -- |
About VistaGen Therapeutics Inc
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an od… Read more